Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03555422 · ClinicalTrials.gov registry record · Phase 3
Maintenance with Selinexor/Placebo After Combination Chemotherapy in Participants with Endometrial Cancer [SIENDO]
A Phase 3 study of Endometrial Cancer, sponsored by Karyopharm Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 263
- Enrollment target
- 20
- Study locations
NCT03555422: Active Phase 3 study of Endometrial Cancer, sponsored by Karyopharm Therapeutics.
NCT03555422 is a Phase 3 study of Endometrial Cancer that is active but no longer recruiting, run by Karyopharm Therapeutics. The registered enrollment target is 263 participants, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03555422, a Phase 3 study of Endometrial Cancer, is active but no longer recruiting, sponsored by Karyopharm Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 263 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a prospective, multicenter, double-blind, placebo-controlled, randomized Phase 3 study. The purpose of the study is to obtain evidence of efficacy for maintenance selinexor in participants with advanced or recurrent endometrial cancer. Participants with primary stage IV or recurrent disease who are in partial or complete response after having completed a single line of at least 12 weeks of taxane-platinum combo therapy will be randomized in a 2:1 manner to maintenance therapy with 80 milligram (mg) with selinexor once weekly (QW) or placebo until progression.
Primary Outcome
Compare progression free survival of the two treatment arms as assessed by the investigator, per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
Conditions Studied
Interventions
- DRUG Selinexor
- DRUG Matching placebo for selinexor
Study Locations (20)
Texas
- Texas Oncology, Austin - Austin
- Texas Oncology DFW - Dallas
- University of Texas Southwestern Medical Center - Dallas
- Texas Oncology DFW - Fort Worth
Florida
- Moffitt Cancer Center - Tampa
- Florida Cancer Specialists (Sarah Cannon Research Institute) - West Palm Beach
Indiana
- Parkview Research Center - Fort Wayne
- Indiana University Simon Cancer Center - Indianapolis
New York
- NYU Langone - New York
- Memorial Sloan Kettering Cancer Center - New York
Arizona
- Arizona Oncology - Tucson
California
- Stanford University - Palo Alto
Illinois
- Gynecological Cancer Institute of Chicago - Oak Lawn
Missouri
- HCA Midwest Health - Kansas City (Sarah Cannon Research Institute) - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2018-01-05 |
| Est. Completion | 2025-12 |
| Phase | Phase 3 |
What the registry record for NCT03555422 still lists
NCT03555422 is an interventional study that assigns participants to a tested intervention. The registered 263 participants enrollment target is mid-sized for trials with a published cap, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Selinexor is the first listed.
NCT03555422 names 20 study sites across 14 states, led by Texas, Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT03555422 about?
NCT03555422 is a clinical study titled "Maintenance with Selinexor/Placebo After Combination Chemotherapy in Participants with Endometrial Cancer [SIENDO]". This is a prospective, multicenter, double-blind, placebo-controlled, randomized Phase 3 study. The purpose of the study is to obtain evidence of efficacy for maintenance selinexor in participants with advanced or recurrent endometrial cancer. Participants with primary stage IV or recurrent disease ...
What is the current status of trial NCT03555422?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 263 participants. The study started on 2018-01-05. Estimated completion is 2025-12.
What conditions does trial NCT03555422 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT03555422?
The interventions under investigation include: Selinexor (DRUG), Matching placebo for selinexor (DRUG).
Who is sponsoring clinical trial NCT03555422?
This trial is sponsored by Karyopharm Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03555422 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03555422's enrollment target sits among peer trials
263 55th of 181 higher than 127 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RECRUITING · Phase 3
-
Vaginal Cuff Brachytherapy Fractionation Study
RECRUITING · Phase 3
-
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
RECRUITING · Phase 3
-
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RECRUITING · Phase 3
-
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04067336 · 263 participants · Phase 1
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
- NCT06234423 · 263 participants · Phase 1
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
- NCT06724627 · 263 participants · NA
Application of the Belle.AI Dermatological Image Reference System for Patient Diagnosis in an Active Clinical Setting
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI